Rapport Therapeutics Inc · Q2 2026 earnings

Briefing

Rapport Therapeutics reported Q2 2026 financial results with a net loss of $56.6 million and continued pipeline advancement.

Rapport Therapeutics Inc. (RAPP), a clinical-stage biotech, reported its Q2 2026 results on August 5, 2026. The company posted a net loss of $56.6 million, up from $26.7 million in the prior year period, driven by increased R&D spending of $51.4 million. Cash position stood at $436.1 million, providing runway into the second half of 2029, as the company advances its RAP-219 Phase 3 program in epilepsy.

• Net loss widened to $56.6 million in Q2 2026 from $26.7 million year-over-year due to higher clinical development costs.
• R&D expenses rose to $51.4 million, reflecting progression of the pipeline including Phase 3 initiation for RAP-219 in focal onset seizures.
• Ended quarter with $436.1 million in cash, cash equivalents and short-term investments, expected to fund operations into H2 2029.
• Pipeline updates include ongoing enrollment in FOCUS 1/2 Phase 3 trials and bipolar mania Phase 2 topline expected in October 2026.

Headline financials

Revenue & EPS history

Cash runway into second half of 2029; multiple clinical catalysts expected including bipolar mania topline in October 2026 and Phase 3 data readouts.